Please assess the completion status of the following clinical trial:

Trial Title: PSUNRISE - Prospective Study Using Remicade in Psoriasis Patients With an Inadequate Response to Etanercept

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have plaque psoriasis despite at least 4 months of treatment with etanercept per current product labeling~* Have psoriatic target lesions that have a PGA score greater than 1 (minimal) at screening~* If receiving methotrexate at screening, must have received methotrexate for at least 3 months and at a stable dose of \<= 25 mg/week for at least 4 weeks prior to screening~* If receiving cyclosporine at screening, must have received cyclosporine at a stable dose of \<= 5 mg/kg daily for at least 4 weeks prior to screening.~Exclusion Criteria:~* Have already received infliximab or adalimumab~* Have shown a previous immediate hypersensitivity response, including anaphylaxis, to an immunoglobulin product~* Have a history of latent or active granulomatous infection, including tuberculosis, histoplasmosis, or coccidioidomycosis, prior to screening~* Have a concomitant diagnosis or any history of Congestive Heart Failure~* Are pregnant, nursing, or planning pregnancy~* Have used systemic corticosteroids within the 4 weeks prior to screening~* Have used topical corticosteroids or have initiated treatment with other topical therapies that could affect psoriasis or Psoriasis Area and Severity Index (PASI) evaluation (e.g., tar, anthralin, calcipotriene, tazarotene, methoxsalen) within 2 weeks prior to screening~* Have used new systemic agents/treatments, other than methotrexate, that can affect psoriasis including, but not limited to, immunosuppressants and/or psoralen plus ultraviolet A light (PUVA) within the 4 weeks prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): infliximabOpen-label 5 mg/kg infliximab infusions at Weeks 0, 2, 6, 14, and 22.

Based on this trial design, predict the completion outcome and termination type (if applicable).